Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages
Authors:
- 9 July 2021
- journal article
- letter
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 21 (14) , 6031-6041
Abstract
Triple-negative breast cancer (TNBC) is an aggressive disease with a high recurrence rate and poor outcomes in clinic. In this study, inspired by the enriched innate immune cell type tumor-associated macrophages (TAMs) in TNBC, we proposed a matrix metalloprotease 2 (MMP2) responsive integrated immunochemotherapeutic strategy to deliver paclitaxel (PTX) and anti-CD47 (aCD47) by detachable immune liposomes (ILips). In the TNBC microenvironment, the “two-in-one” ILips facilitated MMP2-responsive release of aCD47 to efficiently polarize M2 macrophages toward the M1 phenotype to enhance phagocytosis against tumor cells and activate the systemic T cell immune response. Together with the immune effect, the detached PTX-loaded liposomes were internalized in MDA-MB-231 cells to synergistically inhibit tumor cell proliferation and metastasis. In the TNBC-bearing mouse model, PTX-loaded ILips demonstrated superior antitumor efficacy against TNBC and inhibited tumor recurrence. Our integrated strategy represents a promising approach to synchronously enhance immune response and tumor-killing effects, improving the therapeutic efficacy against TNBC.Keywords
Funding Information
- National Natural Science Foundation of China (81973250, 82025032)
- State Key Laboratory of Drug Research, Chinese Academy of Sciences (SIMM2103ZZ-01)
- Chinese Pharmacopoeia Commission (2021Y24)
- the Major International Joint Research Project of Chinese Academy of Sciences (153631KYSB20190020)
This publication has 50 references indexed in Scilit:
- Triple‐negative breast cancer—Role of immunology: A systemic reviewThe Breast Journal, 2019
- FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancerAnnals of Oncology, 2019
- Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung MetastasisAdvanced Science, 2019
- Breast Cancer TreatmentJAMA, 2019
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerNew England Journal of Medicine, 2018
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialThe Lancet Oncology, 2018
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Oncology, 2017
- Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospectsDrug Resistance Updates, 2017
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseNature Reviews Clinical Oncology, 2016
- MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancerAnnals of Oncology, 2007